French specialty drugmaker Ipsen said that its first-half 2006 sales reached 431 million euros, up 6.6% year-on-year, despite a difficult operating environment in its home market.
Revenues from its strategic targeted therapeutic areas, which account foa little over half of group turnover, rose 14% to 221.8 million euros.
In oncology, sales reached 113.6 million euros, up 7%, despite price reductions for Decapeptyl (triptorelin), which grew 10% in volume. Revenues from endocrinology products jumped 22% to 52.4 million euros due to the success in the developments of NutropinAq (controlled-release somatropin), which continued to progress satisfactorily, and from Somatuline/Somatuline Autogel (lanreotide).
Sales of Dysport, Ipsen’s botulinum toxin product, remained strong on the back of good demand in the UK, Latin America and the Middle East, said Ipsen.
